Actively Recruiting
ANCA II - Quality of Life and Functional Outcome in Patients With Anal Cancer
Led by Sahlgrenska University Hospital · Updated on 2023-12-08
600
Participants Needed
1
Research Sites
713 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Anal cancer is a rare disease, but the incidence is rising. About 200 patients will get this type of cancer yearly in Sweden. Curative treatment includes chemotherapy and radiotherapy. The prognosis is good, but some patients will have recurrent or persistent disease after concluded chemo-radiotherapy and will then be offered salvage surgery. Some patients develop distant metastases that can be treated with good results. The aim of this study is to identify and describe functional outcome in patients diagnosed with anal cancer. We will study patients from diagnosis, try to identify early toxicity to treatment and then identify long-term morbidity.
CONDITIONS
Official Title
ANCA II - Quality of Life and Functional Outcome in Patients With Anal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age > 18 years
- Anal squamous carcinoma diagnosed within the last 2 months
You will not qualify if you...
- No informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Dept. of Surgery, Sahlgrenska University Hospital/Ostra
Gothenburg, Sweden, SE 416 85
Actively Recruiting
Research Team
E
Eva Angenete
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here